NASDAQ:IMV
Delisted
IMV Inc. Stock News
$0.82
+0 (+0%)
At Close: Jul 27, 2023
IMV Announces Closing of US$9 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
12:37pm, Tuesday, 20'th Dec 2022
DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--( BUSINESS WIRE )--IMV Inc. (“IMV” or the “Company”) (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company advancing a portfolio of the
IMV Announces US$9 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
08:00am, Friday, 16'th Dec 2022
DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--( BUSINESS WIRE )--IMV Inc. (“IMV” or the “Company”) (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company advancing a portfolio of the
IMV Inc. Announces Initial Data from the Ongoing Phase 2B VITALIZE Trial in Patients with r/r DLBCL
07:05am, Thursday, 15'th Dec 2022
DARTMOUTH, Nova Scotia, & CAMBRIDGE, Mass.--( BUSINESS WIRE )--IMV Inc. (Nasdaq: IMV; TSX: IMV) (“IMV” or the “Company”), a clinical-stage biopharmaceutical company developing a portfolio of i
IMV Commences Trading on the TSX and Nasdaq Post-Reverse Stock Split
07:05am, Tuesday, 13'th Dec 2022
DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--( BUSINESS WIRE )--IMV Inc. (the “Corporation” or “IMV”) (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company developing a portfolio o
IMV Shareholders Approve Reverse Stock Split at 88%
04:05pm, Wednesday, 07'th Dec 2022
DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--( BUSINESS WIRE )--IMV Inc. (the “Corporation”) (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company developing a portfolio of immune-educ
IMV, Inc. (IMV) Q3 2022 Earnings Call Transcript
09:25am, Saturday, 12'th Nov 2022
IMV, Inc. (NASDAQ:IMV ) Q3 2022 Earnings Conference Call November 11, 2022 8:00 AM ET Company Participants Brittany Davison - Chief Accounting Officer Andrew Hall - Chief Executive Officer Jeremy Graf
IMV Inc. to Announce Third Quarter 2022 Results and Host a Conference Call and Webcast on November 11, 2022
07:05am, Tuesday, 08'th Nov 2022
DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.
IMV Inc. to Present at Two Investor Conferences in September
07:05am, Thursday, 01'st Sep 2022
DARTMOUTH, Nova Scotia, & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $IMV #DeliveryPlatform--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies
Why Embark Technology Jumped Around 85%; Here Are 108 Biggest Movers From Friday
07:43am, Monday, 15'th Aug 2022 Benzinga
Gainers
Embark Technology, Inc. (NASDAQ: EMBK) jumped 84.8% to close at $1.07 on Friday after the company reported better-than-expected Q2 EPS results.
Twin Vee Powercats Co. (NASDAQ: VEEE) shares cl
IMV Inc. (IMV) CEO Andrew Hall on Q2 2022 Results - Earnings Call Transcript
02:17pm, Thursday, 11'th Aug 2022
IMV Inc. (NASDAQ:IMV ) Q2 2022 Earnings Conference Call August 11, 2022 8:00 AM ET Company Participants Brittany Davison - Senior Vice President of Finance Andrew Hall - Chief Executive Officer Jeremy
IMV Inc. to Announce Second Quarter 2022 Results and Host a Conference Call and Webcast on August 11, 2022
07:05am, Thursday, 04'th Aug 2022
DARTMOUTH, Nova Scotia, & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $IMV #DeliveryPlatform--IMV Inc. (Nasdaq: IMV; TSX: IMV) (“IMV” or “the Company”), a clinical-stage company developing a portfol
IMV Inc. to Present at the H.C. Wainwright Global Investment Conference
08:05am, Tuesday, 17'th May 2022
DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)--IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX® pla
IMV Inc. (IMV) CEO Andrew Hall on Q1 2022 Results - Earnings Call Transcript
12:13pm, Friday, 13'th May 2022
IMV Inc. (NASDAQ:IMV ) Q1 2022 Earnings Conference Call May 13, 2022 8:00 AM ET Company Participants Andrew Hall – Chief Executive Officer Jeremy Graff – Chief Medical Officer Brittany Davison –
IMV Inc. to Announce First Quarter 2022 Results and Host a Conference Call and Webcast on May 13, 2022
07:05am, Friday, 06'th May 2022
DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV) (“IMV” or “the Company”), a clinical-stage company developing a portfolio of immune-educating thera
IMV to Present at IMMUNOLOGY™ 2022, the AAI Annual Meeting
07:05am, Wednesday, 06'th Apr 2022
DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX® pla
